Global pharma major Lupin Limited has announced the launch of a strategic partnership program to expand the reach of its proprietary long-acting injectable (LAI) platform, PrecisionSphere™, developed by its subsidiary Nanomi B.V.

The program aims to foster collaborations with pharmaceutical companies seeking to extend product lifecycles or develop longer-acting formulations. The announcement follows the U.S. FDA’s recent approval of the first product developed using PrecisionSphere™, validating the platform’s commercial readiness, safety, and efficacy in drug delivery.

Dr. Fabrice Egros, President – Corporate Development at Lupin, said, “With PrecisionSphere™ now validated, we are ready to expand patient access to advanced LAI treatments through new global collaborations. Our alliance management expertise gives us a strong edge in enabling partners to deliver innovative LAI therapies efficiently.”

Dr. Shahin Fesharaki, Chief Scientific Officer at Lupin, added, “PrecisionSphere™ combines innovation, regulatory strength, and scalable manufacturing to help partners bring advanced LAIs to market faster and potentially extend the patent life of their products.”

PrecisionSphere™ offers consistent particle size, shape, and biological properties, ensuring improved injectability and sustained drug release over weeks or months. The platform aims to address major compliance challenges, enhance patient convenience through reduced injection frequency, and support better treatment outcomes across multiple therapeutic areas.

With this initiative, Lupin seeks to accelerate global partnerships and strengthen its position as a leader in advanced drug delivery technologies.